X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (534) 534
Publication (30) 30
Newspaper Article (19) 19
Patent (17) 17
Book Chapter (8) 8
Conference Proceeding (8) 8
Book / eBook (7) 7
Web Resource (6) 6
Magazine Article (3) 3
Book Review (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (260) 260
oncology (213) 213
index medicus (207) 207
female (140) 140
male (140) 140
middle aged (127) 127
lung neoplasms - drug therapy (111) 111
aged (108) 108
adult (104) 104
chemotherapy (102) 102
carcinoma, non-small-cell lung - drug therapy (94) 94
cancer (85) 85
gefitinib (83) 83
lung cancer (80) 80
lung neoplasms - pathology (80) 80
lung neoplasms - genetics (77) 77
mutation (73) 73
treatment outcome (67) 67
carcinoma, non-small-cell lung - genetics (66) 66
open-label (62) 62
antineoplastic combined chemotherapy protocols - therapeutic use (59) 59
erlotinib (58) 58
carcinoma, non-small-cell lung - pathology (57) 57
respiratory system (55) 55
antineoplastic agents - therapeutic use (53) 53
lung cancer, non-small cell (52) 52
receptor, epidermal growth factor - genetics (49) 49
protein kinase inhibitors - therapeutic use (48) 48
care and treatment (47) 47
aged, 80 and over (45) 45
disease-free survival (45) 45
adenocarcinoma (42) 42
neoplasm staging (40) 40
prognosis (39) 39
1st-line treatment (38) 38
research (38) 38
lung neoplasms - mortality (37) 37
therapy (36) 36
hematology, oncology and palliative medicine (35) 35
tumors (35) 35
analysis (34) 34
cell lung-cancer (33) 33
quinazolines - therapeutic use (33) 33
nsclc (31) 31
receptor, epidermal growth factor - antagonists & inhibitors (30) 30
survival analysis (30) 30
carcinoma, non-small-cell lung - mortality (29) 29
patients (29) 29
survival (28) 28
abridged index medicus (27) 27
cancer therapies (27) 27
multicenter (27) 27
cisplatin - administration & dosage (26) 26
tyrosine kinase inhibitors (26) 26
acquired-resistance (25) 25
clinical trials (25) 25
expression (25) 25
studies (25) 25
apoptosis (24) 24
carcinoma (24) 24
prospective studies (24) 24
adenocarcinoma - genetics (23) 23
egfr (23) 23
genetic aspects (23) 23
health aspects (23) 23
metastasis (23) 23
non-small cell lung cancer (23) 23
phase-iii trial (23) 23
medicine, general & internal (22) 22
non-small-cell lung cancer (22) 22
risk factors (22) 22
egfr mutations (21) 21
quality of life (21) 21
survival rate (21) 21
trial (21) 21
adenocarcinoma - drug therapy (20) 20
epidermal growth factor (20) 20
kaplan-meier estimate (20) 20
lung neoplasms - metabolism (20) 20
antineoplastic agents - adverse effects (19) 19
biochemistry (19) 19
carboplatin (19) 19
phase-iii (19) 19
resistance (19) 19
drug therapy (18) 18
epidermal growth factor receptor (18) 18
growth-factor receptor (18) 18
antineoplastic agents - administration & dosage (17) 17
beer (17) 17
cell line, tumor (17) 17
chemistry (17) 17
compositions or test papers therefor (17) 17
condition-responsive control in microbiological orenzymological processes (17) 17
crizotinib (17) 17
disease progression (17) 17
docetaxel (17) 17
enzymology (17) 17
erbb receptors - genetics (17) 17
lung neoplasms - enzymology (17) 17
measuring or testing processes involving enzymes, nucleicacids or microorganisms (17) 17
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Reviews Clinical Oncology, ISSN 1759-4774, 11/2011, Volume 8, Issue 11, pp. 661 - 668
Lung cancer is a complex and often fatal disease. The recent discovery of activating mutations in EGFR and fusion genes involving ALK has set the stage for... 
GENE-MUTATIONS | KRAS MUTATIONS | SUPPORTIVE CARE | PHASE-II TRIAL | GEFITINIB | ONCOLOGY | FACTOR RECEPTOR MUTATIONS | ACQUIRED-RESISTANCE | RANDOMIZED-TRIAL | EGFR MUTATIONS | PREVIOUSLY TREATED PATIENTS | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Clinical Trials as Topic - statistics & numerical data | Humans | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Neoplasm Proteins - antagonists & inhibitors | Molecular Targeted Therapy | Biomarkers, Tumor | Endpoint Determination | Neoplasm Proteins - genetics | Precision Medicine | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Combined Modality Therapy | Lung Neoplasms - therapy | Protein Kinase Inhibitors - administration & dosage | Carcinoma, Non-Small-Cell Lung - therapy | Genes, erbB-1 | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Oncogene Proteins, Fusion - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - drug therapy | Clinical Trials as Topic - methods | Research Design | Usage | Pharmacogenetics | Respiratory agents | Genetic aspects | Research | Lung cancer, Non-small cell | Drug therapy | Health aspects | Risk factors
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2011, Volume 29, Issue 21, pp. 2866 - 2874
Purpose The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and carboplatin/paclitaxel in previously untreated never-smokers and light... 
TRIAL | CHEMOTHERAPY-NAIVE PATIENTS | FACTOR-RECEPTOR GENE | PLACEBO | ONCOLOGY-GROUP | ONCOLOGY | TYROSINE KINASE | SENSITIVITY | EGFR MUTATIONS | MOLECULAR PREDICTORS | PREVIOUSLY TREATED PATIENTS | Immunohistochemistry | Lung Neoplasms - drug therapy | Predictive Value of Tests | Adenocarcinoma - pathology | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Time Factors | Gefitinib | Odds Ratio | Paclitaxel - administration & dosage | Adenocarcinoma - chemistry | Precision Medicine | ErbB Receptors - antagonists & inhibitors | Lung Neoplasms - chemistry | Risk Assessment | Risk Factors | Carboplatin - administration & dosage | In Situ Hybridization, Fluorescence | Logistic Models | Survival Rate | Adenocarcinoma - drug therapy | Biomarkers, Tumor - genetics | Mutation | Carcinoma, Non-Small-Cell Lung - chemistry | Adenocarcinoma of Lung | ErbB Receptors - genetics | Lung Neoplasms - pathology | Patient Selection | Female | Adenocarcinoma - genetics | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Biomarkers, Tumor - analysis | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Gene Dosage | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | ErbB Receptors - analysis | Adenocarcinoma - mortality
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9893, pp. 709 - 719
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 141 - 151
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 577 - 589
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2016, Volume 34, Issue 24, pp. 2858 - 2865
Journal Article
Scientific Reports, ISSN 2045-2322, 05/2016, Volume 6, Issue 1, p. 26591
Journal Article